GlassScriptPhysician profile
Francoise Eve Sutton
NPI 1982747614
$1,057.43
in general payments reported to CMS, 2019-2025
19 companies · $229 in 2025
The $229 reported for 2025 was more than what 78% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $272 · 2023: $249 · 2024: $93.32 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $152.70 | 2022-2023 | Minimed 780g, Mycarelink, Inpen Smart Insulin Delivery System |
| Abbvie INC. | $149.47 | 2021-2025 | |
| Dexcom, INC. | $130.85 | 2021-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $75.77 | 2025 | Sogroya, Wegovy |
| Abbott Laboratories | $71.19 | 2021 | |
| Pfizer INC. | $55.50 | 2022-2025 | |
| Biomarin Pharmaceutical INC. | $50.51 | 2022 | |
| Tolmar, INC. | $49.00 | 2024 | |
| Eton Pharmaceuticals, INC. | $45.62 | 2025 | Alkindi, Increlex, Khindivi |
| Rhythm Pharmaceuticals, INC. | $40.81 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $38.14 | 2022 | |
| Embecta Corp. | $29.22 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Zealand Pharma US, INC. | $29.18 | 2021 | |
| Neurocrine Biosciences, INC. | $27.44 | 2025 | |
| Sequel Med Tech, LLC | $26.15 | 2025 | Twiist |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $24.45 | 2022 | |
| Endo Pharmaceuticals INC. | $23.26 | 2022 | |
| Mannkind Corporation | $20.70 | 2021 | |
| Amryt Pharma Holdings LTD | $17.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francoise Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.